Carmat announces today the launch of a fundraising of around €15 million via the issue of new shares at a fixed price of €3 per share.

This operation is aimed at specialized investors and retail investors (via the PrimaryBid platform).

Stéphane Piat, Chief Executive Officer of Carmat, comments: "This new financing comes at a crucial time, as our sales begin to develop significantly. The progress made both on the commercial front, with in particular the formation of new centers that continue to refer a growing number of patients to us, and in the EFICAS study, whose pace is accelerating, testify to the strong demand for our therapy, interest in which is gradually spreading within the medical community'

' All these promising advances enable us to anticipate substantial growth in our sales over the coming months, with estimated sales of around €14 million for 2024'.

The company estimates its financing needs over the next 12 months, according to its current business plan, at around 45 ME.

Copyright (c) 2024 CercleFinance.com. All rights reserved.